[go: up one dir, main page]

CY1107533T1 - Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2 - Google Patents

Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2

Info

Publication number
CY1107533T1
CY1107533T1 CY20071100330T CY071100330T CY1107533T1 CY 1107533 T1 CY1107533 T1 CY 1107533T1 CY 20071100330 T CY20071100330 T CY 20071100330T CY 071100330 T CY071100330 T CY 071100330T CY 1107533 T1 CY1107533 T1 CY 1107533T1
Authority
CY
Cyprus
Prior art keywords
mutein
cells
native
human
competitives
Prior art date
Application number
CY20071100330T
Other languages
English (en)
Inventor
Armen B Shanafelt
Jeffrey M Greve
Gary Jesmok
Kenneth J Lembach
Gayle D Wetzel
Original Assignee
Aicuris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co. Kg filed Critical Aicuris Gmbh & Co. Kg
Publication of CY1107533T1 publication Critical patent/CY1107533T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Η εφεύρεση αναφέρεται σε ένα πολυπεπτίδιο αποτελούμενο από μία ανθρώπινη μουτεΐνη της IL-2 αριθμημένη σύμφωνα με τη φυσική IL-2 όπου η εν λόγω ανθρώπινη IL-2 έχει υποκατασταθεί σε τουλάχιστον μία από τις θέσεις 20, 88 ή 126, όπου η εν λόγω μουτεΐνη πλεονεκτικά ενεργοποιεί τα κύτταρα Τ σε σχέση με τα κύτταρα ΝΚ. Οι D20H και I, N88G, I, και R, συγκεκριμένα έχουν μία σχετική διαφορική δράση κυττάρων Τ αρκετά μεγαλύτερη από τη φυσική IL-2, με προβλεπόμενη σχετιζόμενη μειωμένη in vivo τοξικότητα. Η εφεύρεση περιλαμβάνει επίσης πολυνουκλεοτίδια τα οποία κωδικοποιούν τις μουτεΐνες της εφευρέσεως, φορείς περιέχοντες τα πολυνουκλεοτίδια, μετασχηματισμένα κύτταρα ξενιστές, φαρμακευτικές συνθέσεις οι οποίες περιέχουν τις μουτεΐνες, και θεραπευτικές μεθόδους αγωγής.
CY20071100330T 1998-05-15 2007-03-09 Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2 CY1107533T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8008098A 1998-05-15 1998-05-15
EP99924232A EP1076704B1 (en) 1998-05-15 1999-05-13 Il-2 selective agonists and antagonists

Publications (1)

Publication Number Publication Date
CY1107533T1 true CY1107533T1 (el) 2013-03-13

Family

ID=22155135

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100330T CY1107533T1 (el) 1998-05-15 2007-03-09 Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2

Country Status (39)

Country Link
EP (1) EP1076704B1 (el)
JP (1) JP4276783B2 (el)
KR (1) KR100607609B1 (el)
CN (2) CN101319247B (el)
AR (1) AR020322A1 (el)
AT (1) ATE351907T1 (el)
AU (1) AU759697B2 (el)
BG (1) BG65139B1 (el)
BR (1) BRPI9910504B1 (el)
CA (1) CA2327349C (el)
CO (1) CO5070701A1 (el)
CU (2) CU23273B7 (el)
CY (1) CY1107533T1 (el)
CZ (1) CZ302071B6 (el)
DE (1) DE69934881T2 (el)
DK (1) DK1076704T3 (el)
DZ (1) DZ2788A1 (el)
ES (1) ES2281175T3 (el)
HK (1) HK1039963B (el)
HN (1) HN1999000075A (el)
HU (1) HU226142B1 (el)
IL (2) IL139136A0 (el)
MY (1) MY130274A (el)
NO (1) NO329235B1 (el)
NZ (1) NZ508098A (el)
PA (1) PA8472601A1 (el)
PE (1) PE20000475A1 (el)
PL (1) PL201675B1 (el)
PT (1) PT1076704E (el)
RO (1) RO122150B1 (el)
RU (1) RU2235729C2 (el)
SI (1) SI20643B (el)
SK (1) SK288100B6 (el)
SV (1) SV1999000061A (el)
TN (1) TNSN99090A1 (el)
TR (1) TR200003354T2 (el)
TW (1) TWI223663B (el)
UA (1) UA73719C2 (el)
WO (1) WO1999060128A1 (el)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
WO2000058456A2 (en) * 1999-03-30 2000-10-05 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
EP1935431A3 (en) 2000-05-15 2008-08-13 Health Research, Inc. Cancer treatments by using a combination of an antibody against her2 and interleukin-2
US6689353B1 (en) * 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
RU2272644C2 (ru) 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
MY139948A (en) * 2000-09-28 2009-11-30 Bayer Corp Enhanced transfection system
US7723102B2 (en) * 2000-09-28 2010-05-25 Bayer Corporation Enhanced transfection system
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1682178B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for cancers expressing the cd40 antigen
JP5744369B2 (ja) * 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
JP2007527242A (ja) * 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CN101244261B (zh) * 2008-03-10 2010-09-15 山东大学 一种含未复性重组蛋白的生物制剂及其制备方法与应用
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
CN102101885B (zh) * 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
DK2637694T3 (da) 2010-11-12 2021-06-07 Nektar Therapeutics KONJUGATER AF EN Il-2-ENHED OG EN POLYMER
WO2012088446A1 (en) * 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
MX340671B (es) 2011-02-10 2016-07-20 Roche Glycart Ag Polipeptidos interleuquina- 2 mutantes.
WO2012119093A1 (en) * 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
WO2015118016A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
SG11201700629TA (en) 2014-08-11 2017-02-27 Delinia Inc Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN108135978A (zh) 2015-10-08 2018-06-08 尼克塔治疗公司 IL-2Rβ选择性激动剂和长效IL-15激动剂的组合
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
EP3280725B1 (en) * 2016-05-04 2020-08-26 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
JP7206190B2 (ja) * 2016-06-22 2023-01-17 ダヴィド・クラッツマン 遺伝的に修飾されたｔリンパ球
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
JP2019532996A (ja) 2016-11-08 2019-11-14 デリニア，インコーポレーテッド 自己免疫疾患を処置するためのｉｌ−２変異体
MX381276B (es) * 2016-12-13 2025-03-12 Delinia Inc Moduladores de linfocitos t reguladores multivalentes.
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. Targeted immunotolerance
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
US20200362058A1 (en) * 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
BR112020002272A2 (pt) * 2017-08-03 2020-07-28 Synthorx, Inc. conjugados de citocina para o tratamento de doenças autoimunes
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN111655718B (zh) 2017-12-19 2025-07-22 Xencor股份有限公司 经过工程化的il-2 fc融合蛋白
WO2019158764A1 (en) 2018-02-16 2019-08-22 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
SG11202007524QA (en) 2018-03-28 2020-09-29 Ascendis Pharma Oncology Div A/S Il-2 conjugates
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
AU2019311233B2 (en) * 2018-07-24 2025-01-09 BioNTech SE IL2 agonists
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020060122A1 (ko) * 2018-09-17 2020-03-26 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
JP7512210B2 (ja) 2018-09-21 2024-07-08 イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド 新規インターロイキン２およびその使用
AU2019409196A1 (en) 2018-12-21 2021-06-17 Jiangsu Hengrui Medicine Co., Ltd. Human interleukin-2 variant or derivative thereof
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
EP4004025A1 (en) 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2 agents and uses thereof
JP2022544236A (ja) * 2019-08-13 2022-10-17 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
EP4073094A1 (en) 2019-12-12 2022-10-19 Iltoo Pharma Interleukin 2 chimeric constructs
JOP20220151A1 (ar) 2019-12-17 2023-01-30 Amgen Inc ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج
EP4087865A2 (en) 2020-01-10 2022-11-16 Bright Peak Therapeutics AG Modified il-2 polypeptides and uses thereof
MX2022008771A (es) 2020-01-14 2022-10-07 Synthekine Inc Metodos y composiciones de muteinas de il2 sesgadas.
US20230210951A1 (en) * 2020-01-14 2023-07-06 Synthekine, Inc. Il2 muteins
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CN115698052A (zh) 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN118271419A (zh) 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
US20240325495A1 (en) 2020-10-29 2024-10-03 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
TW202237171A (zh) 2020-12-04 2022-10-01 美商威特拉公司 使用介白素-2藥劑之方法
CN113308477A (zh) * 2021-04-08 2021-08-27 华南农业大学 一种鸭il-2基因真核表达重组质粒及其制备方法
CA3233075A1 (en) 2021-09-22 2023-03-30 Fortvita Biologics (Singapore) Pte. Ltd. Interleukin-2 mutant and fusion protein thereof
EP4412631A1 (en) 2021-10-06 2024-08-14 Iltoo Pharma Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
CN114875069B (zh) * 2022-04-22 2023-09-15 四川大学 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
TW202413442A (zh) 2022-06-16 2024-04-01 美商希佛隆有限責任公司 抗pd-1抗體減弱之il-2免疫結合物及其用途
KR20250113390A (ko) 2022-09-12 2025-07-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 자폐 스펙트럼 장애 치료에 사용되는 인터루킨-2
FR3140287B1 (fr) 2022-10-03 2025-11-21 Arkema France Procede de granulation de composes azoiques et granules obtenus
CN118056840A (zh) 2022-11-18 2024-05-21 南京诺艾新生物技术有限公司 受体亲和力偏好性的定点偶联聚乙二醇化白介素-2突变体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2003334C1 (ru) * 1988-07-26 1993-11-30 Хем Рисерч, Инк, (US) Способ лечени больных с опухол ми
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13

Also Published As

Publication number Publication date
SV1999000061A (es) 2000-03-14
KR100607609B1 (ko) 2006-08-02
RO122150B1 (ro) 2009-01-30
ES2281175T3 (es) 2007-09-16
CN100366742C (zh) 2008-02-06
HU226142B1 (en) 2008-05-28
AR020322A1 (es) 2002-05-08
CO5070701A1 (es) 2001-08-28
RU2235729C2 (ru) 2004-09-10
SI20643B (sl) 2008-02-29
IL139136A (en) 2009-05-04
BRPI9910504B1 (pt) 2016-08-09
PA8472601A1 (es) 2000-09-29
CZ302071B6 (cs) 2010-09-29
HK1039963A1 (zh) 2002-05-17
SK17242000A3 (sk) 2001-07-10
NO20005762L (no) 2001-01-11
CZ20004213A3 (en) 2001-05-16
PL344407A1 (en) 2001-11-05
MY130274A (en) 2007-06-29
TR200003354T2 (tr) 2001-03-21
CA2327349A1 (en) 1999-11-25
DE69934881D1 (de) 2007-03-08
IL139136A0 (en) 2001-11-25
HK1039963B (zh) 2008-09-05
EP1076704A1 (en) 2001-02-21
WO1999060128A1 (en) 1999-11-25
CA2327349C (en) 2010-10-26
PE20000475A1 (es) 2000-07-07
BR9910504A (pt) 2001-01-09
KR20010043602A (ko) 2001-05-25
CU23273B7 (es) 2008-04-09
NZ508098A (en) 2003-09-26
ATE351907T1 (de) 2007-02-15
JP4276783B2 (ja) 2009-06-10
HUP0101948A3 (en) 2003-08-28
HUP0101948A2 (hu) 2001-09-28
PL201675B1 (pl) 2009-04-30
PT1076704E (pt) 2007-02-28
DE69934881T2 (de) 2007-11-08
SK288100B6 (sk) 2013-07-02
TWI223663B (en) 2004-11-11
DZ2788A1 (fr) 2003-12-01
JP2002515247A (ja) 2002-05-28
CN1309705A (zh) 2001-08-22
SI20643A (sl) 2002-02-28
CU23272A1 (es) 2008-04-09
CN101319247B (zh) 2012-12-12
CN101319247A (zh) 2008-12-10
NO329235B1 (no) 2010-09-20
TNSN99090A1 (fr) 2005-11-10
AU4078499A (en) 1999-12-06
DK1076704T3 (da) 2007-03-12
NO20005762D0 (no) 2000-11-14
UA73719C2 (en) 2005-09-15
BG104929A (en) 2001-09-28
EP1076704B1 (en) 2007-01-17
BG65139B1 (bg) 2007-03-30
HN1999000075A (es) 1999-09-29
AU759697B2 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
CY1107533T1 (el) Επιλεκτικοι συναγωνιστες και ανταγωνιστες της il-2
LTPA2017030I1 (lt) Interferono beta-1A polimero konjugatai ir jų panaudojimas
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR9301944A (pt) Derivado de proteina c,molecula de dna recombinante,celula hospedeira e formulacao farmaceutica
NO952744D0 (no) Cytokinbegrensende midler
ATE251140T1 (de) N-(2 oxoacetyl oder sulphonyl)- pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
BR0111182A (pt) Peptìdeos neuroprotetores
ATE88898T1 (de) Cd4-polypeptidderivate.
BR9507189A (pt) Combinaçoes de proteinas tromboliticamente ativas e anticoagulantes e usos dos mesmos
ATE170220T1 (de) Zusammensetzung verwendbar als therapeutisches mittel gegen chronische virale leberkrankheiten
ATE199167T1 (de) Nichtglykosyliertes fgf-4 und dieses enthaltende präparate
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DK381189A (da) N-2,3-butadienyl-tri- og -tetraaminoalkanderivater og deres anvendelse
ATE76579T1 (de) Interferon-zusammensetzungen.
AU3902489A (en) Non-glycosylated, recombinant human IL2 in the reduced form, the process for obtaining it and its use as a medicament
ATE90359T1 (de) Peptide.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE69334281D1 (de) TCF-II enthaltende medizinische Zusammensetzung
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE59777T1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE69836278D1 (de) Allele formen von menschlichem stat3
IT1216096B (it) L_piroglutamil_l_cisteina, dipeptide ad elevata attivita'anticatarattogena e composizioni farmaceutiche che lo contengono.